291 related articles for article (PubMed ID: 32981502)
1. Phosphodiesterases 5 Inhibitors and Erectile Dysfunction Recovery after Pelvic Surgery: Future Perspectives for New Drugs and New Formulations.
Lombardo R; Tema G; De Nunzio C
Curr Drug Targets; 2021; 22(1):31-37. PubMed ID: 32981502
[TBL] [Abstract][Full Text] [Related]
2. Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis.
Limoncin E; Gravina GL; Corona G; Maggi M; Ciocca G; Lenzi A; Jannini EA
Andrology; 2017 Sep; 5(5):863-872. PubMed ID: 28787547
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
Cui Y; Liu X; Shi L; Gao Z
Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
Kim E; Seftel A; Goldfischer E; Baygani S; Burns P
Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432
[TBL] [Abstract][Full Text] [Related]
6. Exploratory Decision-Tree Modeling of Data from the Randomized REACTT Trial of Tadalafil Versus Placebo to Predict Recovery of Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy.
Montorsi F; Oelke M; Henneges C; Brock G; Salonia A; d'Anzeo G; Rossi A; Mulhall JP; Büttner H
Eur Urol; 2016 Sep; 70(3):529-37. PubMed ID: 26947602
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
[TBL] [Abstract][Full Text] [Related]
8. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
Yafi FA; Sharlip ID; Becher EF
Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
[TBL] [Abstract][Full Text] [Related]
9. The "Kiel Concept" of Long-Term Administration of Daily Low-Dose Sildenafil Initiated in the Immediate Post-Prostatectomy Period: Evaluation and Comparison With the International Literature on Penile Rehabilitation.
Osmonov DK; Jünemann KP; Bannowsky A
Sex Med Rev; 2017 Jul; 5(3):387-392. PubMed ID: 28372960
[TBL] [Abstract][Full Text] [Related]
10. [Phosphodesterase type 5 inhibitors clinical efficiency and role in therapy for erectile dysfunction].
Shodmonova ZR; Gafarov RR; Allazov SA; Giyasov SI
Urologiia; 2021 May; (2):135-140. PubMed ID: 33960173
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta-analysis of randomized controlled trials.
Liao X; Qiu S; Bao Y; Wang W; Yang L; Wei Q
World J Urol; 2019 Jun; 37(6):1061-1074. PubMed ID: 30523399
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
[TBL] [Abstract][Full Text] [Related]
13. A comparison of different oral therapies versus no treatment for erectile dysfunction in 196 radical nerve-sparing radical prostatectomy patients.
Natali A; Masieri L; Lanciotti M; Giancane S; Vignolini G; Carini M; Serni S
Int J Impot Res; 2015; 27(1):1-5. PubMed ID: 25056808
[TBL] [Abstract][Full Text] [Related]
14. Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT).
Montorsi F; Brock G; Stolzenburg JU; Mulhall J; Moncada I; Patel HR; Chevallier D; Krajka K; Henneges C; Dickson R; Büttner H
Eur Urol; 2014 Mar; 65(3):587-96. PubMed ID: 24169081
[TBL] [Abstract][Full Text] [Related]
15. Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
Mostafa T
Sex Med Rev; 2016 Jul; 4(3):270-284. PubMed ID: 27871960
[TBL] [Abstract][Full Text] [Related]
16. Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management.
Nandipati KC; Raina R; Agarwal A; Zippe CD
Drugs Aging; 2006; 23(2):101-17. PubMed ID: 16536634
[TBL] [Abstract][Full Text] [Related]
17. The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue.
Zucchi A; Costantini E; Scroppo FI; Silvani M; Kopa Z; Illiano E; Petrillo MG; Cari L; Nocentini G
Andrology; 2019 Nov; 7(6):804-817. PubMed ID: 31350821
[TBL] [Abstract][Full Text] [Related]
18. Lodenafil.
Alshehri YM; Al-Majed AA; Attwa MW; Bakheit AH
Profiles Drug Subst Excip Relat Methodol; 2022; 47():113-147. PubMed ID: 35396013
[TBL] [Abstract][Full Text] [Related]
19. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
Ventimiglia E; Capogrosso P; Montorsi F; Salonia A
Expert Opin Drug Saf; 2016; 15(2):141-52. PubMed ID: 26752541
[TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction.
Megas G; Papadopoulos G; Stathouros G; Moschonas D; Gkialas I; Ntoumas K
BJU Int; 2013 Jul; 112(2):E169-76. PubMed ID: 23253640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
